It seems that the pro-business policy the new administration has been implementing to promote Korea’s industries is not benefiting the domestic pharmaceutical companies at all. Rather, the companies have expressed their regrets on how the authorities have been implementing policies that hinder their corporate activities, such as those that lower generic drug prices.

Although the policy to reduce the price of generics has not been implemented yet, the industry believes the policy will surface with the release of the 2nd Comprehensive National Health Insurance Plan in the second half of this year.

In particular, the drug price-reducing policy is expected to come to the fore because Profes